Navigation Links
Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer

WHIPPANY, N.J., April 20 /PRNewswire/ -- As part of a Research and Development partnership between Halo Pharmaceutical and DeMelleBioPharma, LLC, Dr. George Bobotas joins Halo Pharmaceutical as Chief Scientific Officer. Halo and DeMelle are working closely together in this alliance on the development of several client products. "I am excited at the potential synergies between these two dynamic companies and the opportunity to work closely together with a talented group of pharmaceutical professionals," said Dr. George Bobotas.

Dr. Bobotas has been President and Managing Partner of DeMelleBioPharma, LLC since 2008. He was employed at Reliant Pharmaceuticals (a wholly owned subsidiary of GlaxoSmithKline plc) for eight years in the position of Vice President, Scientific Affairs. At Reliant, he led teams for the development and commercialization of products with combined marketing penetration of over US$1.00 Billion including Lovaza and Antara among many others. Prior to Reliant, he was the founder and Executive Director of the Covance Center for CNS Research. Earlier in his career, Dr. Bobotas has held senior positions at Mylan Laboratories, Somerset Pharmaceuticals and Forest Laboratories. He is the inventor of 24 patents and patent applications. Dr. Bobotas received his Ph.D. in Biochemistry from the City University of New York. He has also received graduate training in Industrial Pharmacy and Physical Chemistry. He is a member of the American Association of Pharmaceutical Scientists, American College of Clinical Pharmacology and American Society for Experimental Neurotherapeutics.

"Having Dr. Bobotas on its team, Halo now has the capability to develop more complicated products and provide services to its existing and future clients with challenging technical transfers and new Product Development opportunities. We are excited to have George on board," said Mohd Asif, Chief Financial Officer of Halo Pharmaceutical.

Halo capabilities include an impressive array of formulation services, Commercial operations for solid dosage forms, and operations for the aseptic filling of topical ointments, solid dosage forms(tablets and capsules), liquids, suppositories, associated packaging (tablet, powder, liquids and HUD) and ample laboratory space for formulation development, pre-clinical and clinical supplies and support of commercial operations. An additional asset is the site's capability to manufacture controlled substances (C2-C5) and an API manufacturing unit with an outstanding track record of meeting DEA requirements.

About Halo Pharmaceutical

Halo Pharmaceutical, headquartered in Whippany, NJ, is a full-service, specialty pharmaceutical company, offering state-of-the-art contract manufacturing, early stage formulation development and laboratory services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important life cycle products. Contract manufacturing capabilities include the ability to conduct aseptic filling, granulation, blending, tableting, coating, packaging, and related warehousing operations. Halo Pharmaceutical is a privately-held company.

About DeMelleBioPharma

DeMelle participates in new drug development through strategic alliances across a broad range of pharmaceutical dosage forms and therapeutic areas. The founders of DeMelle have a significant amount of experience in the pharmaceutical industry. They were responsible in bringing a number of novel drug products to commercialization.

SOURCE Halo Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
2. Sun Pharmaceutical Extends Tender Offer for Taro
3. Amylin Pharmaceuticals Reports First Quarter Financial Results
4. Star Scientific Reports on Filing Patent Application for Zero-Nitrosamine Tobacco Curing Process, Product Development by Rock Creek Pharmaceuticals
5. Tigris Pharmaceuticals Appoints Pedro Granadillo as Chairman of Board of Directors
6. Vion Pharmaceuticals New Drug Application for Onrigin(TM)Accepted For Review by the FDA
7. Generic Pharmaceuticals Offer Exciting Growth Opportunities in Tanzania, Reveals Frost & Sullivan
8. Letter From Carl Icahn to Amylin Pharmaceutical, Inc.
9. Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements
10. Tianyin Pharmaceutical Co., Inc. Series A Preferred Shareholders Approved Cash Dividend to Common Stockholders
11. Lionbridge Announces Partnership with Open Text to Streamline Regulatory Compliance Solutions for Pharmaceutical Companies
Post Your Comments:
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
Breaking Medicine Technology: